

Draft Guidance on Emtricitabine; Rilpivirine Hydrochloride; Tenofovir Alafenamide Fumarate

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Emtricitabine; Rilpivirine hydrochloride; Tenofovir alafenamide fumarate

Dosage Form; Route: Tablet; oral

Recommended Studies: Two studies

1. Type of study: Fasting

Design: Single-dose, two-way, crossover *in-vivo*

Strength: 200 mg; Eq. 25 mg (base); Eq. 25 mg (base)

Subjects: Healthy males and non-pregnant, non-lactating females, general population.

Additional comments:

- 1) The study population should consist of healthy subjects at least 18 years old, in good general health, with no clinically relevant health conditions identified by a detailed medical history, full physical examination, and laboratory screening, and not on any of the drugs or herbal products contraindicated in the product labeling.
- 2) At a minimum, prescreening laboratory evaluation should include pregnancy testing for women, and, for all subjects, a complete blood count as well as testing for liver function, acute or chronic active hepatitis, hepatitis antigen carrier status, illicit drug use, and renal function.
- 3) Renal function testing should include creatinine clearance, urine glucose, and urine protein.
- 4) To minimize risks, the following additional, minimum safety monitoring (prior to dosing and after each dosing period) should be conducted during the BE trial: pregnancy test for women, liver function tests, and renal function testing, including creatinine clearance, urine glucose, and urine protein.

2. Type of study: Fed

Design: Single-dose, two-way, crossover *in-vivo*

Strength: 200 mg; Eq. 25 mg (base); Eq. 25 mg (base)

Subjects: Healthy males and non-pregnant, non-lactating females, general population.

Additional comments: Same as above

Analytes to measure (in appropriate biological fluid): Emtricitabine, Rilpivirine and Tenofovir in plasma

Bioequivalence based on (90% CI): Emtricitabine, Rilpivirine and Tenofovir

Waiver request of in-vivo testing: N/A

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website available to the public at the following location: <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).